Calcium channel agonists and dystonia in the mouse.
Identifieur interne : 000281 ( Ncbi/Merge ); précédent : 000280; suivant : 000282Calcium channel agonists and dystonia in the mouse.
Auteurs : H A Jinnah [États-Unis] ; J P Sepkuty ; T. Ho ; S. Yitta ; T. Drew ; J D Rothstein ; E J HessSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2000.
English descriptors
- KwdEn :
- 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester (pharmacology), Animals, Brain Mapping, Calcium Channel Agonists (pharmacology), Calcium Channels (physiology), Dose-Response Relationship, Drug, Dystonia (physiopathology), Electroencephalography (drug effects), Electromyography (drug effects), Locomotion (drug effects), Mice, Mice, Inbred C3H, Mice, Inbred C57BL, Neurologic Examination (drug effects), Pyrroles (pharmacology).
- MESH :
- chemical , pharmacology : 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester, Calcium Channel Agonists, Pyrroles.
- chemical , physiology : Calcium Channels.
- drug effects : Electroencephalography, Electromyography, Locomotion, Neurologic Examination.
- physiopathology : Dystonia.
- Animals, Brain Mapping, Dose-Response Relationship, Drug, Mice, Mice, Inbred C3H, Mice, Inbred C57BL.
Abstract
Systemic administration of the L-type calcium channel agonists +/-Bay K 8644 or FPL 64176 causes a characteristic pattern of motor dysfunction in normal C57BL/6J mice that resembles generalized dystonia. There is no associated change in the electroencephalogram, confirming that the motor disorder does not reflect epileptic seizures. However, the electromyogram reveals an increase in baseline motor unit activity with prolonged phasic discharges consistent with dystonia. The duration and severity of dystonia is dependent on the dose administered and the age of the animal at testing. The effects are transient, with the return of normal motor behavior 1-4 hours after treatment. Similar effects can be provoked by intracerebral administration of small amounts of the drugs, indicating a centrally mediated response. Dystonia can be attenuated by co-administration of dihydropyridine L-type calcium channel antagonists (nifedipine, nimodipine, and nitrendipine) but not by non-dihydropyridine antagonists (diltiazem, verapamil, and flunarizine). These results implicate abnormal function of L-type calcium channels in the expression of dystonia in this model.
PubMed: 10830422
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003F70
- to stream PubMed, to step Curation: 003F70
- to stream PubMed, to step Checkpoint: 004024
Links to Exploration step
pubmed:10830422Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Calcium channel agonists and dystonia in the mouse.</title><author><name sortKey="Jinnah, H A" sort="Jinnah, H A" uniqKey="Jinnah H" first="H A" last="Jinnah">H A Jinnah</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland 21287</wicri:regionArea><wicri:noRegion>Maryland 21287</wicri:noRegion></affiliation></author><author><name sortKey="Sepkuty, J P" sort="Sepkuty, J P" uniqKey="Sepkuty J" first="J P" last="Sepkuty">J P Sepkuty</name></author><author><name sortKey="Ho, T" sort="Ho, T" uniqKey="Ho T" first="T" last="Ho">T. Ho</name></author><author><name sortKey="Yitta, S" sort="Yitta, S" uniqKey="Yitta S" first="S" last="Yitta">S. Yitta</name></author><author><name sortKey="Drew, T" sort="Drew, T" uniqKey="Drew T" first="T" last="Drew">T. Drew</name></author><author><name sortKey="Rothstein, J D" sort="Rothstein, J D" uniqKey="Rothstein J" first="J D" last="Rothstein">J D Rothstein</name></author><author><name sortKey="Hess, E J" sort="Hess, E J" uniqKey="Hess E" first="E J" last="Hess">E J Hess</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:10830422</idno><idno type="pmid">10830422</idno><idno type="wicri:Area/PubMed/Corpus">003F70</idno><idno type="wicri:Area/PubMed/Curation">003F70</idno><idno type="wicri:Area/PubMed/Checkpoint">004024</idno><idno type="wicri:Area/Ncbi/Merge">000281</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Calcium channel agonists and dystonia in the mouse.</title><author><name sortKey="Jinnah, H A" sort="Jinnah, H A" uniqKey="Jinnah H" first="H A" last="Jinnah">H A Jinnah</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland 21287</wicri:regionArea><wicri:noRegion>Maryland 21287</wicri:noRegion></affiliation></author><author><name sortKey="Sepkuty, J P" sort="Sepkuty, J P" uniqKey="Sepkuty J" first="J P" last="Sepkuty">J P Sepkuty</name></author><author><name sortKey="Ho, T" sort="Ho, T" uniqKey="Ho T" first="T" last="Ho">T. Ho</name></author><author><name sortKey="Yitta, S" sort="Yitta, S" uniqKey="Yitta S" first="S" last="Yitta">S. Yitta</name></author><author><name sortKey="Drew, T" sort="Drew, T" uniqKey="Drew T" first="T" last="Drew">T. Drew</name></author><author><name sortKey="Rothstein, J D" sort="Rothstein, J D" uniqKey="Rothstein J" first="J D" last="Rothstein">J D Rothstein</name></author><author><name sortKey="Hess, E J" sort="Hess, E J" uniqKey="Hess E" first="E J" last="Hess">E J Hess</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester (pharmacology)</term><term>Animals</term><term>Brain Mapping</term><term>Calcium Channel Agonists (pharmacology)</term><term>Calcium Channels (physiology)</term><term>Dose-Response Relationship, Drug</term><term>Dystonia (physiopathology)</term><term>Electroencephalography (drug effects)</term><term>Electromyography (drug effects)</term><term>Locomotion (drug effects)</term><term>Mice</term><term>Mice, Inbred C3H</term><term>Mice, Inbred C57BL</term><term>Neurologic Examination (drug effects)</term><term>Pyrroles (pharmacology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester</term><term>Calcium Channel Agonists</term><term>Pyrroles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Calcium Channels</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Electroencephalography</term><term>Electromyography</term><term>Locomotion</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dystonia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Brain Mapping</term><term>Dose-Response Relationship, Drug</term><term>Mice</term><term>Mice, Inbred C3H</term><term>Mice, Inbred C57BL</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Systemic administration of the L-type calcium channel agonists +/-Bay K 8644 or FPL 64176 causes a characteristic pattern of motor dysfunction in normal C57BL/6J mice that resembles generalized dystonia. There is no associated change in the electroencephalogram, confirming that the motor disorder does not reflect epileptic seizures. However, the electromyogram reveals an increase in baseline motor unit activity with prolonged phasic discharges consistent with dystonia. The duration and severity of dystonia is dependent on the dose administered and the age of the animal at testing. The effects are transient, with the return of normal motor behavior 1-4 hours after treatment. Similar effects can be provoked by intracerebral administration of small amounts of the drugs, indicating a centrally mediated response. Dystonia can be attenuated by co-administration of dihydropyridine L-type calcium channel antagonists (nifedipine, nimodipine, and nitrendipine) but not by non-dihydropyridine antagonists (diltiazem, verapamil, and flunarizine). These results implicate abnormal function of L-type calcium channels in the expression of dystonia in this model.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">10830422</PMID><DateCreated><Year>2000</Year><Month>10</Month><Day>02</Day></DateCreated><DateCompleted><Year>2000</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>May</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Calcium channel agonists and dystonia in the mouse.</ArticleTitle><Pagination><MedlinePgn>542-51</MedlinePgn></Pagination><Abstract><AbstractText>Systemic administration of the L-type calcium channel agonists +/-Bay K 8644 or FPL 64176 causes a characteristic pattern of motor dysfunction in normal C57BL/6J mice that resembles generalized dystonia. There is no associated change in the electroencephalogram, confirming that the motor disorder does not reflect epileptic seizures. However, the electromyogram reveals an increase in baseline motor unit activity with prolonged phasic discharges consistent with dystonia. The duration and severity of dystonia is dependent on the dose administered and the age of the animal at testing. The effects are transient, with the return of normal motor behavior 1-4 hours after treatment. Similar effects can be provoked by intracerebral administration of small amounts of the drugs, indicating a centrally mediated response. Dystonia can be attenuated by co-administration of dihydropyridine L-type calcium channel antagonists (nifedipine, nimodipine, and nitrendipine) but not by non-dihydropyridine antagonists (diltiazem, verapamil, and flunarizine). These results implicate abnormal function of L-type calcium channels in the expression of dystonia in this model.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jinnah</LastName><ForeName>H A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepkuty</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yitta</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Drew</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>E J</ForeName><Initials>EJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS01985</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS33592</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002120">Calcium Channel Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>120934-96-5</RegistryNumber><NameOfSubstance UI="C071658">FPL 64176</NameOfSubstance></Chemical><Chemical><RegistryNumber>71145-03-4</RegistryNumber><NameOfSubstance UI="D001498">3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001498">3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001931">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002120">Calcium Channel Agonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015220">Calcium Channels</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004421">Dystonia</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004569">Electroencephalography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004576">Electromyography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008124">Locomotion</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008809">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011758">Pyrroles</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10830422</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Drew, T" sort="Drew, T" uniqKey="Drew T" first="T" last="Drew">T. Drew</name><name sortKey="Hess, E J" sort="Hess, E J" uniqKey="Hess E" first="E J" last="Hess">E J Hess</name><name sortKey="Ho, T" sort="Ho, T" uniqKey="Ho T" first="T" last="Ho">T. Ho</name><name sortKey="Rothstein, J D" sort="Rothstein, J D" uniqKey="Rothstein J" first="J D" last="Rothstein">J D Rothstein</name><name sortKey="Sepkuty, J P" sort="Sepkuty, J P" uniqKey="Sepkuty J" first="J P" last="Sepkuty">J P Sepkuty</name><name sortKey="Yitta, S" sort="Yitta, S" uniqKey="Yitta S" first="S" last="Yitta">S. Yitta</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Jinnah, H A" sort="Jinnah, H A" uniqKey="Jinnah H" first="H A" last="Jinnah">H A Jinnah</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000281 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000281 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:10830422
|texte= Calcium channel agonists and dystonia in the mouse.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:10830422" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |